Search results
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Zacks via Yahoo Finance· 3 days agoGSK currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 6 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Zacks via Yahoo Finance· 3 days agoModerna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 2 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
CNBC Daily Open: Apple upgrades Siri with AI
CNBC· 3 days agoThe S&P 500 and the Nasdaq Composite inched to record highs ahead of the Federal Reserve's interest rate decision. Shares of Apple fell 1.9% after the iPhone maker delivered its long-awaited ...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 6 days agoThe following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. Protagonist is a clinical-stage biopharmaceutical ...
Daily Brief: Apple’s AI strategy
Quartz· 3 days ago“Apple Intelligence” is a new collection of AI features that is focused on personal products, and privacy is a huge goal of executives.
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
Zacks via Yahoo Finance· 6 days agoHalozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its...
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Zacks· 4 days agoFree Report) announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy ...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 7 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
